Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR) ligand, radiation can be delivered to cancer...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2022-12-01
Col·lecció:	Frontiers in Medicine
Matèries:	actinium-225 neuroendocrine tumor peptide receptor radionuclide therapy (PRRT) targeted α-particle therapy SSTR SSTR antagonist
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1034315/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!